Nicotredole (Tryptamide) (Tryptamide) is an orally active analgesic and anti-inflammatory agent. Nicotredole exhibits evident anti-inflammatory effects of potency comparable with Phenylbutazone. Nicotredole has only weak ulcerogenic activity.

Nicotredole inhibits prostaglandin synthetase activity in an in vitro assay [1].

Nicotredole exhibits anti-inflammatory properties as evidenced by its effectiveness in reducing carrageenin-induced paw edema in rats. Additionally, it has been shown to counteract pyrogen-induced hyperthermia, offer analgesic benefits, extend hexobarbital-induced sleep duration, and suppress locomotor activities in both rats and mice. Intraperitoneally (i.p.), Nicotredole holds lethal doses (LD50) of 1260 mg/kg for male rats and 1980 mg/kg for male mice, whereas orally (p.o.), its LD50 values are 8.5 g/kg for male rats and 9.3 g/kg for male mice. Administered either orally or intraperitoneally at a dose of 25 mg/kg, Nicotredole is rapidly absorbed and eliminated, with half-lives ranging from 4.92 to 17.5 minutes for absorption and 55.72 to 74.52 minutes for elimination. It achieves maximum concentration (C max) levels of 11-13 μg/cm^3 within 30 minutes, resulting in area under the curve (AUC) values between 21.40 and 27.30 μg•h/cm^3.